Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
40 studies found for:    "Vatalanib"
Show Display Options
Rank Status Study
1 Completed
Has Results
Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Conditions: Brain and Central Nervous System Tumors;   Sarcoma
Intervention: Drug: vatalanib
2 Completed
Has Results
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: vatalanib
3 Completed PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia;   Agnogenic Myeloid Metaplasia;   Chronic Myelogenous Leukemia
Interventions: Drug: Imatinib Mesylate (Gleevec);   Drug: PTK 787 (vatalanib)
4 Completed
Has Results
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Vatalanib;   Drug: Gemcitabine
5 Terminated PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Intervention: Drug: PTK787
6 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
7 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
8 Completed Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Conditions: Ovarian Cancer;   Endometrial Cancer;   Cervical Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Breast Cancer
Interventions: Drug: Docetaxel;   Drug: PTK787
9 Completed PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Condition: Sarcoma
Intervention: Drug: PTK787/ZK222584
10 Completed Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
Intervention: Drug: vatalanib
11 Completed Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PTK787
12 Completed Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery
Condition: Melanoma (Skin)
Intervention: Drug: vatalanib
13 Completed Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: hydroxyurea;   Drug: imatinib mesylate;   Drug: vatalanib
14 Completed Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Conditions: Kidney Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: RAD001 (everolimus);   Drug: PTK787 (vatalanib)
15 Completed PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: PTK787/ZK 222584
16 Completed Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Conditions: Tumors;   Neoplasm Metastasis
Intervention: Drug: PTK787/ZK 222584 (vatalanib)
17 Completed PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Condition: Neoplasm
Intervention: Drug: PTK787/ZK222584
18 Completed PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Conditions: Refractory Malignancy;   Advanced Malignancies
Intervention: Drug: PTK787/ZK222584 and Bevacizumab
19 Unknown  Trial of PTK787/ZK 222584 Plus Paclitaxel
Condition: Metastatic Non-hematologic Malignancies
Interventions: Drug: PTK787/ZK 222584;   Drug: paclitaxel
20 Completed Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Conditions: Von Hippel-Lindau Disease;   Central Nervous System Capillary Hemangioblastoma;   Retinal Capillary Hemangioblastoma
Intervention: Drug: PTK787/ZK 222584

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.